Two dozen academic physicians from around the U.S. with expertise in point-of-care ultrasound—and no vested interest in POCUS industry players—recently tested and compared four commercially available POCUS handhelds.

The FDA has greenlit a whole-body MRI machine that uses deep learning and advanced image processing to wring “elevated image quality” from a magnet with only 0.55 Tesla field strength.

The FDA is notifying patients and referrers of another breast-imaging service’s slide into noncompliance with regulatory standards for image quality.

Fewer than 40% of rural counties in the U.S. can offer residents any access to point-of-care ultrasound, while nearly 90% of their metropolitan counterparts have POCUS aplenty. 

A clinical trial pitting MRI against a burgeoning PET/CT technique has found the de facto defending champion better at revealing the presence of any grade of prostate cancer.

Two emerging MRI techniques show promise as all-in-one imaging tests for patients with pain in and below the lower back due to changes in the sacroiliac joint.

The FDA is warning patients and referrers about an imaging business near the nation’s capital that has fumbled away its mammography accreditation.

The FDA has cleared a focused-ultrasound developer to compare the safety and efficacy of acoustic energy for treating prostate cancer against the more conservative approach of active surveillance.